Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rurioctocog alfa pegol - Takeda

Next Previous
Drug Profile

Rurioctocog alfa pegol - Takeda

Alternative Names: Adynovate; Adynovi; BAX-855; EHL rFVIII PEG; Extended half-life recombinant FVIII; Full-length longer-acting rFVIII; LA rFVIII PEG; PEG factor VIII; PEGylated recombinant factor VIII; PEGylated rFVIII; SHP-660; TAK 660

Latest Information Update: 09 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Baxter International; Nektar Therapeutics
  • Developer Baxter International; Nektar Therapeutics; Takeda
  • Class Antihaemorrhagics; Blood coagulation factors; Coagulants; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Factor VIII replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Haemophilia A

Most Recent Events

  • 31 Jul 2025 Preregistration for Haemophilia A in China (IV) (Takeda pipeline, November 2025)
  • 29 Oct 2024 Takeda completes a phase III trial in Haemophilia A (In children, In infants, In neonates, Treatment-naive) in USA, Austria, Belgium, Bulgaria, Canada, Czech Republic, Denmark, Finland, France, Germany, Hong Kong, Hungary, Italy, South Korea, Spain, Malaysia, Norway, Singapore, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, Netherlands (IV) (NCT02615691)
  • 05 Sep 2024 Takeda completes a phase III trial for Haemophilia A (In children, In adolescents, In adults, Treatment-experienced, Prevention) in China (IV) (NCT05707351)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top